[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-334847-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-334847-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","advances-and-challenges-in-gene-therapy-strategies-for-pediatric-cancer-a-comprehensive-update","Advances and challenges in gene therapy strategies for pediatric cancer: a comprehensive update","","Gene therapy for pediatric cancer targets malignant disease while aiming to reduce toxicity compared with conventional treatments that have improved survival yet remain insufficiently precise. This review critically evaluates recent progress and persistent obstacles, highlighting emerging vectors and delivery platforms such as adeno-associated viruses and non-viral systems. It focuses on CAR T-cell therapies and adaptations for solid tumors, alongside genetic and epigenetic complexities including tumor heterogeneity and a dynamic tumor microenvironment. Ethical issues for children—consent and long-term follow-up—are also assessed, together with challenges translating preclinical findings and navigating regulatory pathways to enable safe, effective, and ethically responsible innovation.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/advances-and-challenges-in-gene-therapy-strategies-for-pediatric-cancer-a-comprehensive-update/334847/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/advances-and-challenges-in-gene-therapy-strategies-for-pediatric-cancer-a-comprehensive-update/334847.png","ImageObject",300,407,{"name":42,"@type":43},"Ivy","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-12","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is gene therapy considered promising for pediatric cancer?","Question",{"text":63,"@type":64},"Gene therapy addresses the need for more targeted and less toxic interventions, and it aims to overcome limitations of conventional treatments despite improved survival.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What delivery platforms are discussed for pediatric gene therapy?",{"text":68,"@type":64},"The review highlights viral vectors such as adeno-associated viruses and non-viral platforms, emphasizing their potential to match pediatric tumor biology.",{"name":70,"@type":61,"acceptedAnswer":71},"What major challenges remain for applying gene therapy to pediatric cancers?",{"text":72,"@type":64},"Key hurdles include tumor heterogeneity and the dynamic tumor microenvironment, along with translation gaps between preclinical models and pediatric cancer biology, plus regulatory and ethical barriers.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},334847,1790774151,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},549758252649,"https://ap-avatar.wpscdn.com/avatar/8000253669c5317157?_k=1778319167496531819","TYPE Review  \nPUBLISHED 21 May 2024  \nDOI 10.3389/fmolb.2024.1382190  \nOPEN ACCESS  \nEDITED BY  \nGeorgina Gonzalez-Avila,  \nNational Institute of Respiratory DiseasesMexico (INER), Mexico  \nREVIEWED BY  \nSameh A. Abdelnour, Zagazig University, Egypt Chao Chen,  \nNanjing University of Chinese Medicine, China  \n*CORRESPONDENCE  \nAlireza Nourazarian,  \n [noorazarian_a@khoyums.ac.ir](noorazarian_a@khoyums.ac.ir)  \n†These authors have contributed equally to this work  \nRECEIVED 05 February 2024  \nACCEPTED 27 March 2024  \nPUBLISHED 21 May 2024  \nCITATION  \nMoaveni AK, Amiri M, Shademan B, Farhadi A, Behroozi J and Nourazarian A (2024), Advancesand challenges in gene therapy strategies for pediatric cancer: a comprehensive update.  \nFront. Mol. Biosci. 11:1382190 .  \ndoi: 10.3389/fmolb.2024.1382190  \nCOPYRIGHT  \n© 2024 Moaveni, Amiri, Shademan, Farhadi, Behroozi and Nourazarian. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nAdvances and challenges in gene therapy strategies for pediatric cancer: a comprehensive update  \nAmir Kian Moaveni 1†, Maryam Amiri 1, Behrouz Shademan 2†, Arezoo Farhadi 3, Javad Behroozi 4 and Alireza Nourazarian 5*  \n1Pediatric Urology and Regenerative Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran, 2Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran, 3Department of Genetics and Molecular Medicine, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran, 4 Department of Cell and Molecular Biology, Faculty of Biological Sciences, Kharazmi University, Tehran, Iran, 5Department of Basic Medical Sciences, Khoy University of Medical Sciences, Khoy, Iran  \nPediatric cancers represent a tragic but also promising area for gene therapy. Although conventional treatments have improved survival rates, there is still a need for targeted and less toxic interventions. This article critically analyzes recent advances in gene therapy for pediatric malignancies and discusses the challenges that remain. We explore the innovative vectors and delivery systems that have emerged, such as adeno-associated viruses and non-viral platforms, which show promise in addressing the unique pathophysiology of pediatric tumors. Speciﬁcally, we examine the ﬁeld of chimeric antigen receptor (CAR) T-cell therapies and their adaptation for solid tumors, which historically have been more challenging to treat than hematologic malignancies. We also discuss the genetic and epigenetic complexities inherent to pediatric cancers, such as tumor heterogeneity and the dynamic tumor microenvironment, which pose signiﬁcant hurdles for gene therapy. Ethical considerations speciﬁc to pediatric populations, including consent and long-term follow-up, are also analyzed. Additionally, we scrutinize the translation of research from preclinical models that often fail to mimic pediatric cancer biology to the regulatory landscapes that can either support or hinder innovation. In summary, this article provides an up-to-date overview of gene therapy in pediatric oncology, highlighting both the rapid scientiﬁc progress and the substantial obstacles that need to be addressed. Through this lens, we propose a roadmap for future research that prioritizes the safety, efﬁcacy, and complex ethical considerations involved in treating pediatric patients. Our ultimate goal is to move from incremental advancements to transformative therapies.  \nKEYWORDS  \ngene therapy, pediatric cancer, CRISPR-Cas9, gene editing, delivery systems  \nAbbreviation: CAR, chimeric antigen receptor; ALL, acute lymphoblastic leukemia; C","cbCaiobUKRDb0jL1","https://ap.wps.com/l/cbCaiobUKRDb0jL1","pdf",1533387,18,"English","# Introduction\n## Gene therapy advances for pediatric malignancies\n## Vectors and delivery systems\n## CAR T-cell therapies for pediatric cancers\n## Genetic and epigenetic complexities\n## Ethical considerations in pediatric gene therapy\n## Translational and regulatory challenges","[{\"question\":\"Why is gene therapy considered promising for pediatric cancer?\",\"answer\":\"Gene therapy addresses the need for more targeted and less toxic interventions, and it aims to overcome limitations of conventional treatments despite improved survival.\"},{\"question\":\"What delivery platforms are discussed for pediatric gene therapy?\",\"answer\":\"The review highlights viral vectors such as adeno-associated viruses and non-viral platforms, emphasizing their potential to match pediatric tumor biology.\"},{\"question\":\"What major challenges remain for applying gene therapy to pediatric cancers?\",\"answer\":\"Key hurdles include tumor heterogeneity and the dynamic tumor microenvironment, along with translation gaps between preclinical models and pediatric cancer biology, plus regulatory and ethical barriers.\"}]","Advances and challenges in gene therapy strategies for pediatric cancer: a comprehensive update | PDF",1790008559,45]